Literature DB >> 29511827

Impulse control disorders in Parkinson's disease.

Ana Marques1,2, Franck Durif1,2, Pierre-Olivier Fernagut3,4,5,6.   

Abstract

Impulse control disorders (ICD) are frequent side effects of dopamine replacement therapy (DRT) used in Parkinson's disease (PD) with devastating consequences on the patients and caregivers. ICD are behavioural addictions including compulsive gambling, shopping, sexual behaviour, and binge eating that are mainly associated with dopamine D2/D3 agonists. Their management is a real clinical challenge due to the lack of therapeutic alternative. Clinical studies have identified demographic and clinical risk factors for ICD such as younger age at disease onset, male gender, prior history of depression or substance abuse, REM sleep behaviour disorders and higher rate of dyskinesia. PD patients with ICD may also have a specific pattern of dopaminergic denervation in the ventral striatum. Specific evaluation tools have now been designed to better evaluate the severity and impact of ICD in PD. Patients with ICD display altered processing of reward and loss, and decisional bias associated with altered activity in cortical and subcortical areas such as the orbitofrontal cortex, amygdala, insula, anterior cingular cortex, and ventral striatum. Preclinical studies have demonstrated that D2/D3 agonists induce impairments in behavioural processes likely relevant to ICD such as risk-taking behaviour, preference for uncertainty, perseverative responding and sustained drive to engage in gambling-like behaviour. Whether interactions between dopamine denervation and DRT significantly contribute to the pathogenesis of ICD remains poorly understood so far, although features unique to PD have been identified in patients with ICD. Large-scale longitudinal studies are needed to better identify subjects with increased risk to develop ICD and develop therapeutic options.

Entities:  

Keywords:  Addiction; Dopamine agonist; Impulse control disorders; Parkinson’s disease

Mesh:

Substances:

Year:  2018        PMID: 29511827     DOI: 10.1007/s00702-018-1870-8

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  126 in total

1.  Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.

Authors:  Daniel Weintraub; Juergen Koester; Marc N Potenza; Andrew D Siderowf; Mark Stacy; Valerie Voon; Jacqueline Whetteckey; Glen R Wunderlich; Anthony E Lang
Journal:  Arch Neurol       Date:  2010-05

2.  Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling.

Authors:  Roberto Cilia; Ji Hyun Ko; Sang Soo Cho; Thilo van Eimeren; Giorgio Marotta; Giovanna Pellecchia; Gianni Pezzoli; Angelo Antonini; Antonio P Strafella
Journal:  Neurobiol Dis       Date:  2010-03-22       Impact factor: 5.996

3.  Kleptomania, an unusual impulsive control disorder in Parkinson's disease?

Authors:  Alejandro Bottini Bonfanti; Emilia M Gatto
Journal:  Parkinsonism Relat Disord       Date:  2010-03-04       Impact factor: 4.891

4.  Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.

Authors:  J P Doucet; Y Nakabeppu; P J Bedard; B T Hope; E J Nestler; B J Jasmin; J S Chen; M J Iadarola; M St-Jean; N Wigle; P Blanchet; R Grondin; G S Robertson
Journal:  Eur J Neurosci       Date:  1996-02       Impact factor: 3.386

5.  Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study.

Authors:  Daniel Weintraub; Kimberly Papay; Andrew Siderowf
Journal:  Neurology       Date:  2013-01-08       Impact factor: 9.910

6.  Selective Inactivation of Striatal FosB/ΔFosB-Expressing Neurons Alleviates L-DOPA-Induced Dyskinesia.

Authors:  Michel Engeln; Matthieu F Bastide; Estelle Toulmé; Benjamin Dehay; Mathieu Bourdenx; Evelyne Doudnikoff; Qin Li; Christian E Gross; Eric Boué-Grabot; Antonio Pisani; Erwan Bezard; Pierre-Olivier Fernagut
Journal:  Biol Psychiatry       Date:  2014-07-15       Impact factor: 13.382

7.  Effects of selective dopaminergic compounds on a delay-discounting task.

Authors:  Mikhail N Koffarnus; Amy H Newman; Peter Grundt; Kenner C Rice; James H Woods
Journal:  Behav Pharmacol       Date:  2011-08       Impact factor: 2.293

Review 8.  Rodent models of impulsive-compulsive behaviors in Parkinson's disease: How far have we reached?

Authors:  M Angela Cenci; Veronica Francardo; Sean S O'Sullivan; Hanna S Lindgren
Journal:  Neurobiol Dis       Date:  2015-08-30       Impact factor: 5.996

9.  Effect of impulse control disorders on disability and quality of life in Parkinson's disease patients.

Authors:  Amy L Phu; Zheyu Xu; Vlasios Brakoulias; Neil Mahant; Victor S C Fung; Gregory De Moore; Andrew Martin; Vladan Starcevic; Martin Krause
Journal:  J Clin Neurosci       Date:  2013-09-10       Impact factor: 1.961

10.  Reinforcing properties of Pramipexole in normal and parkinsonian rats.

Authors:  Michel Engeln; Serge H Ahmed; Caroline Vouillac; François Tison; Erwan Bezard; Pierre-Olivier Fernagut
Journal:  Neurobiol Dis       Date:  2012-08-23       Impact factor: 5.996

View more
  6 in total

Review 1.  Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.

Authors:  Taiji Tsunemi; Genko Oyama; Shinji Saiki; Taku Hatano; Jiro Fukae; Yasushi Shimo; Nobutaka Hattori
Journal:  Mov Disord       Date:  2021-04-25       Impact factor: 9.698

Review 2.  Manganese-Enhanced Magnetic Resonance Imaging: Overview and Central Nervous System Applications With a Focus on Neurodegeneration.

Authors:  Ryan A Cloyd; Shon A Koren; Jose F Abisambra
Journal:  Front Aging Neurosci       Date:  2018-12-13       Impact factor: 5.750

3.  What drugs modify the risk of iatrogenic impulse-control disorders in Parkinson's disease? A preliminary pharmacoepidemiologic study.

Authors:  Nakyung Jeon; Marco Bortolato
Journal:  PLoS One       Date:  2020-01-07       Impact factor: 3.240

4.  Clinical and Clinical-Pharmacogenetic Models for Prediction of the Most Common Psychiatric Complications Due to Dopaminergic Treatment in Parkinson's Disease.

Authors:  Sara Redenšek; Barbara Jenko Bizjan; Maja Trošt; Vita Dolžan
Journal:  Int J Neuropsychopharmacol       Date:  2020-11-26       Impact factor: 5.176

5.  Impulse Control Disorders in Parkinson's Disease. A Brief and Comprehensive Review.

Authors:  Emilia M Gatto; Victoria Aldinio
Journal:  Front Neurol       Date:  2019-04-17       Impact factor: 4.003

6.  Assessment of Repetitive and Compulsive Behaviors Induced by Pramipexole in Rats: Effect of Alpha-Synuclein-Induced Nigrostriatal Degeneration.

Authors:  Mélina Decourt; Eric Balado; Haritz Jiménez-Urbieta; Maureen Francheteau; Pierre-Olivier Fernagut; Marianne Benoit-Marand
Journal:  Biomedicines       Date:  2022-02-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.